Julia Krzykalla
Overview
Explore the profile of Julia Krzykalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rucker F, Bullinger L, Cocciardi S, Skambraks S, Luck T, Weber D, et al.
Blood Adv
. 2024 Sep;
8(23):6067-6080.
PMID: 39348668
Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently...
2.
Rucker F, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, et al.
Hemasphere
. 2024 Jul;
8(7):e123.
PMID: 39011127
No abstract available.
3.
Mai E, Goldschmid H, Miah K, Bertsch U, Besemer B, Hanel M, et al.
Lancet Haematol
. 2024 Feb;
11(2):e101-e113.
PMID: 38302221
Background: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well...
4.
Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz G, Bullinger L, et al.
Leukemia
. 2023 Oct;
37(11):2336-2337.
PMID: 37789148
No abstract available.
5.
Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz G, Bullinger L, et al.
Leukemia
. 2023 Aug;
37(11):2187-2196.
PMID: 37591941
To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted...
6.
Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn M, Schroeder T, et al.
Lancet Haematol
. 2023 May;
10(7):e495-e509.
PMID: 37187198
Background: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the...
7.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson R, Ottone T, et al.
Leukemia
. 2022 Aug;
36(9):2218-2227.
PMID: 35922444
The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus...
8.
Dohner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al.
Blood Adv
. 2022 Apr;
6(18):5345-5355.
PMID: 35486475
We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year...
9.
Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, et al.
Front Immunol
. 2022 Apr;
13:877477.
PMID: 35464403
Background: Endothelial dysfunction is associated with two main complications of chimeric antigen receptor T (CAR-T) cell therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This study...
10.
Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj B, Robrecht S, Krzykalla J, et al.
Nat Commun
. 2021 Sep;
12(1):5395.
PMID: 34518531
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform...